乳腺癌的发病机制及临床治疗的研究进展
关键词:
乳腺癌；发病机制；治疗；进展摘要
乳腺癌作为全球女性健康的第二大威胁，其研究进展备受瞩目。本文深入探讨乳腺癌发病机制，涵盖遗传因素、基因突变、激素水平及不良生活方式等多方面，剖析其发病根源。同时，全面阐述乳腺癌治疗临床研究新进展，涉及手术、放疗、化疗及内分泌治疗等，旨在为临床治疗决策提供科学依据，助力改善患者预后，延长生存期，提高生活质量。
参考
[1] 全球疾病负担癌症协作组. 1990 年至2015 年全球、区域和国家32 种癌症组的癌症发病率、死亡率、寿命损失年数、残疾年数和残疾调整生命年数. JAMA Oncol. 2017 年4 月1
日;3(4):524-548.
[2] Möller S, Mucci LA, Harris JR, Scheike T, Holst K, Halekoh U, Adami HO, Czene K, Christensen K, Holm NV, Pukkala E, Skytthe A, Kaprio J, Hjelmborg JB. The Heritability of Breast Cancer among Women in the Nordic Twin Study of Cancer. Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):145-50. doi: 10.1158/1055-9965.
EPI-15-0913.
[3] Sampson JN, Wheeler WA, Yeager M, et al. Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. J Natl Cancer Inst. 2015 Oct 12;107(12):djv279. doi: 10.1093/jnci/djv279. Erratum in: J Natl Cancer Inst. 2016 Apr;108(4).
[4] Severi G, Southey MC, English DR, et al. Epigenome-wide methylation in DNA from peripheral blood as a marker of risk for breast cancer. Breast Cancer Res Treat. 2014 Dec;148(3):665-73.
[5] Yang Y, Wu L, Shu XO, et al. Genetically Predicted Levels of DNA Methylation Biomarkers and Breast Cancer Risk: Data From 228 951 Women of European Descent. J Natl Cancer Inst. 2020 Mar 1;112(3):295-304.
[6] Allott EH, Hursting SD. Obesity and cancer: mechanistic insights from transdisciplinary studies. Endocr Relat Cancer. 2015 Dec;22(6):R365-86.
[7] Zeitzer JM, Nouriani B, Rissling MB, Sledge GW, Kaplan KA, Aasly L, Palesh O, Jo B, Neri E, Dhabhar FS, Spiegel D. Aberrant nocturnal cortisol and disease progression in women with breast cancer. Breast Cancer Res Treat. 2016 Jul;158(1):43-50.
[8] 乳腺癌激素因素协作组. 绝经后激素治疗的类型和时机与乳腺癌风险：全球流行病学证据的个体参与者荟萃分析. Lancet. 2019 年9 月28 日;394(10204):1159-1168.
[9] 北美更年期学会. 北美更年期学会2012 年激素治疗立场声明. 更年期. 2012 年3 月;19(3):257-71.
[10] Cottet V, Touvier M, Fournier A, Touillaud MS, Lafay L, Clavel-Chapelon F, Boutron-Ruault MC. Postmenopausal breast cancer risk and dietary patterns in the E3N-EPIC prospective cohort study. Am J Epidemiol. 2009 Nov 15;170(10):1257-67.
[11] Castelló A, Pollán M, Buijsse B, Ruiz A, Casas AM, Baena-Cañada JM, Lope V, Antolín S, Ramos M, Muñoz M, Lluch A, de Juan-Ferré A, Jara C, Jimeno MA, Rosado P, Díaz E, Guillem V, Carrasco E, Pérez-Gómez B, Vioque J, Boeing H, Martín M; GEICAM researchers. Spanish Mediterranean diet and other dietary patterns and breast cancer risk: case-control EpiGEICAM study. Br J Cancer. 2014 Sep 23;111(7):1454-62.
[12] Hirko KA, Willett WC, Hankinson SE, Rosner BA, Beck AH, Tamimi RM, Eliassen AH. Healthy dietary patterns and risk of breast cancer by molecular subtype. Breast Cancer Res Treat. 2016 Feb;155(3):579-88.
[13] McTiernan A, Friedenreich CM, Katzmarzyk PT, Powell KE, Macko R, Buchner D, Pescatello LS, Bloodgood B, Tennant B, Vaux-Bjerke A, George SM, Troiano RP, Piercy KL; 2018 PHYSICAL ACTIVITY GUIDELINES ADVISORY COMMITTEE*. Physical Activity in Cancer Prevention and Survival: A Systematic Review. Med
Sci Sports Exerc. 2019 Jun;51(6):1252-1261.
[14] Ibrahim EM, Al-Homaidh A. Physical activity and survival after breast cancer diagnosis: meta-analysis of published studies. Med Oncol. 2011 Sep;28(3):753-65.
[15] Stick LB, Yu J, Maraldo MV, Aznar MC, Pedersen AN, Bentzen SM, Vogelius IR. Joint Estimation of Cardiac Toxicity and Recurrence Risks After Comprehensive Nodal Photon Versus Proton Therapy for Breast Cancer. Int J Radiat Oncol Biol Phys. 2017 Mar 15;97(4):754-761.
[16] Tanaka S, Iwamoto M, Kimura K, Matsunami N, Morishima H, Yoshidome K, Nomura T, Morimoto T, Yamamoto D, Tsubota Y, Kobayashi T, Uchiyama K. Phase II Study of Neoadjuvant Anthracycline-Based Regimens Combined With Nanoparticle Albumin-Bound Paclitaxel and Trastuzumab for Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer. Clin Breast Cancer. 2015 Jun;15(3):191-6.
[17] Wapnir IL, Anderson SJ, Mamounas EP, Geyer CE Jr, Jeong JH, Tan-Chiu E, Fisher B, Wolmark N. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol. 2006 May 1;24(13):2028-37.
[18] Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, Cataliotti L, Westenberg AH, Klinkenbijl JH, Orzalesi L, Bouma WH, van der Mijle HC, Nieuwenhuijzen GA, Veltkamp SC, Slaets L, Duez NJ, de Graaf PW, van Dalen T, Marinelli A, Rijna H, Snoj M, Bundred NJ, Merkus JW, Belkacemi Y, Petignat P, Schinagl DA, Coens C, Messina CG, Bogaerts J, RutgersEJ. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014 Nov;15(12):1303-10.
[19] Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011 Aug 27;378(9793):771-84.
[20] Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, Mouret-Reynier MA, Sohn JH, Taylor D, Harnden KK, Khong H, Kocsis J, Dalenc F, Dillon PM, Babu S, Waters S, Deleu I, García Sáenz JA, Bria E, Cazzaniga M, Lu J, Aftimos P, Cortés J, Liu S, Tonini G, Laurent D, Habboubi N, Conlan MG, Bardia A. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J Clin Oncol. 2022 Oct 1;40(28):3246-3256.
